TECHNODERMA MEDICINES
TechnoDerma Medicines is a private clinical-stage biopharmaceutical company. They develop programs that include innovative therapies for the treatment of androgenetic alopecia, atopic dermatitis/eczema, psoriasis, and lupus erythematosus, among other diseases.
TECHNODERMA MEDICINES
Industry:
Biotechnology
Founded:
2014-01-01
Address:
Xuzhou, Jiangsu, China
Country:
China
Website Url:
http://www.tkskin.com
Total Employee:
11+
Status:
Active
Contact:
0573-82795671
Email Addresses:
[email protected]
Total Funding:
10 M CNY
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Content Delivery Network Mobile Non Scaleable Content Apache Apple Mobile Web App Capable Common Name Invalid DigiCert SSL Encryption Everywhere
Similar Organizations
Allevi
Allevi offers bioprinters that enable users to experiment with any biomaterial, work with any cell line, and print in any geometry.
Biomeme
Biomeme is a real-time PCR thermocycler that attaches to iPhone 5s and enables DNA diagnostics and real-time disease surveillance.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
TalexMedical
The proud producer of Infantear – a revolutionary Class I medical device for the treatment of external ear deformities in newborns.
Tarsa Therapeutics
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Investors List
Wanwan Venture Capital
Wanwan Venture Capital investment in Series A - TechnoDerma Medicines
Kaitai Capital
Kaitai Capital investment in Series A - TechnoDerma Medicines
Viva BioInnovator
Viva BioInnovator investment in Series A - TechnoDerma Medicines
Chengdu Biocity
Chengdu Biocity investment in Series A - TechnoDerma Medicines
Linden Asset
Linden Asset investment in Series A - TechnoDerma Medicines
Oceanpine Capital
Oceanpine Capital investment in Series A - TechnoDerma Medicines
CDH Investments
CDH Investments investment in Series A - TechnoDerma Medicines
Official Site Inspections
http://www.tkskin.com
- Host name: 43.252.229.202
- IP address: 43.252.229.202
- Location: Sheung Wan Hong Kong
- Latitude: 22.2909
- Longitude: 114.15
- Timezone: Asia/Hong_Kong
More informations about "TechnoDerma Medicines"
特科罗生物科技（成都）有限公司
特科罗治疗雄激素性脱发全球首创新药临床二期a试验证实：tdm-105795促进雄激素性脱发患者毛发生长. 2024年2月5日特科罗生物科技（成都）有限公司（“特科罗”），一家专注皮肤疾病新药研发的临床阶段公司，很高兴地宣布：外用涂抹 …See details»
TechnoDerma Medicines Inc. - tkskin.com
Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial . CHENGDU, China – April , 2024 (XYZ Newswire) Technoderma Medicines, Inc. (“the …See details»
TechnoDerma Medicines - Crunchbase Company Profile & Funding
Organization. TechnoDerma Medicines . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. TechnoDerma Medicines is engaged …See details»
企业介绍 - 特科罗生物科技（成都）有限公司
联系方式. 地址：成都天府国际生物城（双流区生物城中路二段18号2栋1401） 电话：028-62420070 邮编：610219See details»
Jiaxing Tekeluo Biotechnology Co. Ltd. - Drug pipelines, Patents ...
May 1, 2024 www.tkskin.com. Holding Company | 2014 | Sichuan Sheng, China | www.tkskin.com. Last update 02 May 2024. Overview. Pipeline. Deal. Translational Medicine. …See details»
Technoderma Medicines, Inc. (特科罗生物科技（成都）有限公司)
了解Technoderma Medicines, Inc. (特科罗生物科技（成都）有限公司)公司的药物管线，治疗领域，技术平台，以及它的5项临床试验, 37篇新闻，疾病领域:免疫系统疾病，技术平台:小分子化 …See details»
TechnoDerma Medicines, Inc. (嘉兴特科罗生物科技有限公司) - 药 …
1、乐纯生物获数亿元C轮融资，持续拓展海外业务 上海乐纯生物技术有限公司（简称“乐纯生物”）宣布完成数亿元人民币的C轮融资，由诺和诺德控股股东Novo Holdings（诺和控股）、泛 …See details»
TechnoDerma Medicines - Viva BioInnovator
Viva BioInnovator. No. 50, Lane 63, Faraday Road, Zhangjiang High-Tech Park, Shanghai, 201203, China.See details»
Technoderma Medicines Completes Phase 1 Dose Escalation …
Dec 4, 2023 Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial …See details»
Technoderma Medicines Initiates TDM-105795 Androgenetic
CHENGDU, China, April 18, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the …See details»
管理层团队 - 特科罗生物科技（成都）有限公司
李冠群 博士 药物研发生物学副总. 李博士在北京医科大学(现北大医学部)完成了本科到博士阶段的学习，曾在北京医科大学...See details»
Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 …
Feb 5, 2024 Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial …See details»
Technoderma Medicines Completes Phase 1 Dose Escalation
CHENGDU, China, Dec. 4, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has …See details»
Technoderma Medicines Phase 2 Clinical Trial of TDM-105795
CHENGDU, China, Feb. 5, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has …See details»
TechnoDerma Announces Achievement of FIH with TDM-105795 …
TechnoDerma Medicines Inc. (www.tkskin.com) announced that the phase I clinical trial of its lead small molecule drug TDM-105795 in topical formulation completed first dosing of two subjects …See details»
Technoderma Medicines Doses TDM-105795 in Phase 1b (MAD) …
February 28, 2022 — . Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing in its Phase …See details»
Technoderma Medicines Advances TDM-180935 Atopic Dermatitis …
CHENGDU, China, April 29, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company …See details»
特科罗生物宣布在美I期临床试验新进展：治疗脱发的小分子药 …
May 10, 2021 近期，嘉兴特科罗生物科技有限公司（ www.tkskin.com ）宣布其全球领先小分子药物TDM-105795的I期临床试验在美国西部圣地亚哥皮肤临床研究中心TCR（Therapeutics …See details»
公司新闻 - 特科罗生物科技（成都）有限公司 - tkskin.com
特科罗生物宣布在美I期临床试验新进展：治疗脱发的小分子药物TDM-105795完成首次患者给药. 近期，嘉兴特科罗生物科技有限公司（www.tkskin.com）宣布其全球领先小分子药物TDM …See details»
Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis …
SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun …See details»